Email this article 
Effektivnost' lecheniya tyazhelogo predmenstrual'nogo sindroma drospirenonsoderzhashchim preparatom
- Authors: Ledina AV1, Prilepskaya VN1
-
Affiliations:
- Issue: Vol 14, No 3 (2012)
- Pages: 53-57
- Section: Articles
- URL: https://gynecology.orscience.ru/2079-5831/article/view/33312
- ID: 33312
Cite item
Full Text
Abstract
References
- Аганезова Н.В. Ассоциация функциональных вариантов генов транспортеров серотонина и дофамина с психовегетативными нарушениями у больных с предменструальным синдромом. VII Всероссийская научно-практическая конференция с международным участием «Молекулярная диагностика - 2010». Сб. тр. Под ред. В.И.Покровского. 2010. Т. 3 (разд. 13): 4, 5.
- Прилепская В.Н., Межевитинова Е.А. Предменструальный синдром. Гинекология. 2005; 7 (4): 210-4.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, 1994.
- Andréen L et al. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 2009; 34 (8): 1121-32.
- Finocchi C, Ferrari M. Female reproductive steroids and neuronal excitability. Neurol Sci 2011; 32: S31-5.
- Freeman EW, Sondheimer SJ. Premenstrual dysphoric disorder: recognition and treatment. Primary Care Companion. J Clin Psychiatry 2003; 5: 30-9.
- Halbreich U et al. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 1986; 74 (6): 576-86.
- Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol 1994; 170 (5 Pt 2): 1499-507.
- Machado RB et al. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 2011; 7 (1): 19-30.
- Marr J et al. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet 2011; 113 (2): 103-7.
- Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med 2008; 53 (Suppl. 9): 721-8.
- O'Brien PM et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health 2011; 14 (1): 13-21.
- OelkersW. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004; 217 (1-2): 255-61.
- Oinonen K, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002; 70 (3): 229-40.
- Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61 (2): 105-11.
- Pearlstein TB et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation Contraception 2005; 72 (6): 414-21.
- Pinkerton JV. The menstrual cycle-mood disorder tandem: Screening, diagnosis, and treatment. OBG Management 2011; 23 (12): 24-9.
- Rapkin AJ et al. Oral contraceptives and neuroactive steroids. Pharmacol Biochem Behav 2006; 84 (4): 628-34.
- Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception 2005; 71 (1): 1-7.
- Steiner M, Born L. Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 2000; 15 (Suppl. 3): S5-17.
- Usman SB et al. Hormonal management of premenstrual syndrome. Best Pract Res Clin Obstet Gynaecol 2008; 22 (2): 251-60.
- Yonkers KA et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106 (3): 492-501.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).